Fostering Good Bioethics Practices Among the European Biotechnology Industry: Bioethics Report on Genetic Testing


The project: “From GMP to GBP – From Good Manufacturing Practices To Good Bioethical Practices" is a Specific Targeted Research Project  funded by the European Commission, Sixth Framework Programme. 

The project aims at integrating bioethical practices as an intrinsic part of industrial standards, just as Good Clinical Practices (GCP) or Good Manufacturing Practices (GMP) are. These standards of Good Bioethical Practices (GBP) would allow the industry to define its own issues and recommendations inform to European Union legislators and relevant authorities. The project also aims to improve understanding of bioethical issues, based on the current practices of biotech companies, as well as to elaborate clear and independent positions on bioethics, based on regularly updated  scientific and technological data.
The final step will involve disseminating this information to the industry and to society. The project is piloted by the French biotechnology  association, France Biotech, in partnership with a consortium comprising the European Association of Bioindustries, EuropaBio, and national biotechnology associations  from Estonia (the Estonian Biotechnology Association), France (France Biotech), Hungary (the Hungarian Biotechnology Association), Sweden (SwedenBio) and  Spain (ASEBIO), as well as the French Institute for Health and Medical Research (INSERM U558).  
Genetic testing is one biotech application that has attracted the most attention as regards ethical aspects and the corresponding framework. The indications concerning best practices for research in genetics and for pharmacogenetics are less clear than for clinical diagnostic genetics. The present challenges are anchored in new developments. They include:  
• high throughput techniques generating large amounts of data,  
• uncertainty on the clinical significance of much preliminary genetic data,  
• limits of patentability,  
• assessment of clinical utility and return of results to research participants. 
In addition, during the period of the present project, the considerable development of directto-consumer genetic tests has generated a need to consider regulation in this domain.
 At present, there is no universal standard definition of genetic testing. A broad definition was used by the projects’ EU expert group for genetic testing, “any test that yields genetic data”. Genetic data or information relates to inherited or acquired properties that are transmitted during cell division and that affect subsequent generations of offspring, or cells and tissues. This definition needs to be specified.  
As no general ethical and regulatory frameworks exist, considerable divergences remain as to ways of taking into account the development of genetic testing. In general, this activity is not yet regulated within the EU Member States. Nor  are there any specific rules or framework for validation of genetic tests, including pharmacogenetic tests at EU level. 
There should also be measures taken to prevent undesirable consequences in society as a result of genetic testing, including:  
• greater public information and education,  
• an assessment of validity (in particular of the clinical utility of tests)  
• ensuring there is information on existing validated tests,  
• genetic counselling on clinical utility and  
• conditions of access.   
Confidentiality, privacy and autonomy need to be considered.  Protection from discrimination, irrespective of confidentiality issues, applies to genetic data as it does to other data. Personal medical data including genetic data must not be used to discriminate against individuals, including with regard to ethnicity